Developing formulations that differ significantly from those that are established also pervades lipid-based nanomedicines. For instance, the compositional similarity across approved liposomal nanomedicines suggests a "benchmarking" approach whereby an established formulation is subjected to minor adjustments including lipid types and/or compositions to encapsulate a new API (Table ). While this may be part of the reason for the numbers of successfully approved lipid-based nanomedicines, this approach is not infallible, as there are still many examples of formulations at the preclinical and clinical levels that are curbed from reaching further stages of development and translation . With the current approach to formulation development, achieving innovation and translatability is not easy. As such, it is necessary to implement strategies that enable researchers to explore questions of innovation (e.g., lipid compositions, synthetic vs. naturally-derived lipids, surface modifications, etc.) in a way that is feasible and practical to carry out.